This HTML5 document contains 45 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n16http://linked.opendata.cz/resource/drugbank/drug/DB06655/identifier/chebi/
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n17http://linked.opendata.cz/resource/drugbank/drug/DB06655/identifier/uniprotkb/
n25http://linked.opendata.cz/resource/mesh/concept/
foafhttp://xmlns.com/foaf/0.1/
n18http://linked.opendata.cz/resource/drugbank/drug/DB06655/identifier/wikipedia/
n20http://linked.opendata.cz/resource/drugbank/drug/DB06655/identifier/pharmgkb/
n6http://linked.opendata.cz/resource/drugbank/dosage/
n23http://www.rxlist.com/
n13http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
n21http://linked.opendata.cz/resource/drugbank/drug/DB06655/identifier/kegg-drug/
n22http://linked.opendata.cz/resource/drugbank/drug/DB06655/identifier/drugbank/
n4http://linked.opendata.cz/resource/drugbank/patent/
n12http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
n24http://linked.opendata.cz/ontology/mesh/
n3http://linked.opendata.cz/ontology/drugbank/
n19http://linked.opendata.cz/resource/drugbank/drug/DB06655/identifier/national-drug-code-directory/
n10http://www.drugs.com/cdi/
n14http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n8http://linked.opendata.cz/resource/atc/
n7http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB06655
rdf:type
n3:Drug
n3:description
Victoza contains liraglutide, an analog of human GLP-1 and acts as a GLP-1 receptor agonist. The peptide precursor of liraglutide, produced by a process that includes expression of recombinant DNA in Saccharomyces cerevisiae, has been engineered to be 97% homologous to native human GLP-1 by substituting arginine for lysine at position 34. Liraglutide is made by attaching a C-16 fatty acid (palmitic acid) with a glutamic acid spacer on the remaining lysine residue at position 26 of the peptide precursor.
n3:dosage
n6:271B4DC9-363D-11E5-9242-09173F13E4C5 n6:271B4DC8-363D-11E5-9242-09173F13E4C5
n3:generalReferences
# Russell-Jones D: Molecular, pharmacological and clinical aspects of liraglutide, a once-daily human GLP-1 analogue. Mol Cell Endocrinol. 2009 Jan 15;297(1-2):137-40. Epub 2008 Nov 25. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/19041364 # Vilsboll T: Liraglutide: a new treatment for type 2 diabetes. Drugs Today (Barc). 2009 Feb;45(2):101-13. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/19343230 # http://dailymed.nlm.nih.gov/dailymed/archives/fdaDrugInfo.cfm?archiveid=15776 # Malm-Erjefalt M, Bjornsdottir I, Vanggaard J, Helleberg H, Larsen U, Oosterhuis B, van Lier JJ, Zdravkovic M, Olsen AK: Metabolism and excretion of the once-daily human glucagon-like peptide-1 analog liraglutide in healthy male subjects and its in vitro degradation by dipeptidyl peptidase IV and neutral endopeptidase. Drug Metab Dispos. 2010 Nov;38(11):1944-53. doi: 10.1124/dmd.110.034066. Epub 2010 Aug 13. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/20709939
n3:group
approved
n3:halfLife
approximately 13 hours.
n3:indication
For use in/treatment of diabetes mellitus type 2.
owl:sameAs
n12:DB06655 n13:DB06655
dcterms:title
Liraglutide
adms:identifier
n16:71193 n17:P01275 n18:Liraglutide n19:0169-4060-13 n20:PA165958364 n21:D06404 n22:DB06655
n3:mechanismOfAction
Liraglutide is an acylated GLP-1 (Glucagon-Like Peptide-1) receptor agonist. Liraglutide upregulates intracellular cAMP resulting in the release of insulin given elevated blood glucose concentrations. Glucagon secretion is also decreased in a glucose-dependent fashion by liraglutide.
n3:patent
n4:2264243 n4:6268343
n3:routeOfElimination
Excreted in urine and feces, 6% and 5%, respectively.
n3:synonym
N²⁶-(hexadecanoyl-gamma-glutamyle)-[34-arginine]GLP-1-(7-37)-peptide NNC 90-1170 Liraglutida Victoza NN 2211 Liraglutidum NN2211 N²⁶-(N-Hexadecanoyl-L-gamma-glutamyl)-[34-L-arginine]glucagon-like peptide 1-(7-37)-peptide NN-2211 Arg34Lys26-(N-ε-(γ-Glu(N-α-hexadecanoyl)))-GLP-1[7-37]
n3:toxicity
In a clinical trial, one patient with type 2 diabetes experienced a single overdose of Victoza 17.4 mg subcutaneous (10 times the maximum recommended dose). Effects of the overdose included severe nausea and vomiting requiring hospitalization. No hypoglycemia was reported. The patient recovered without complications. In the event of overdosage, appropriate supportive treatment should be initiated according to the patient’s clinical signs and symptoms. RISK OF THYROID C-CELL TUMORS
n3:volumeOfDistribution
SubQ 0.6 mg is approximately 13L Intravenous is approximately 0.07L/kg
n3:proteinBinding
>98%
n24:hasConcept
n25:M0405743
foaf:page
n10:liraglutide.html n23:victoza-drug.htm
n3:Molecular-Formula
n14:271B4DCB-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n14:271B4DCA-363D-11E5-9242-09173F13E4C5
n7:hasATCCode
n8:A10BX07
n3:absorption
Maximum concentrations of liraglutide are achieved at 8-12 hours after dose. The mean peak and total exposures of liraglutide were 35 ng/mL and 960 ng·h/mL, respectively, for a subQ single dose of 0.6 mg. After subcutaneous single dose administrations, Cmax and AUC of liraglutide increased proportionally over the therapeutic dose range of 0.6 mg to 1.8 mg. At 1.8 mg Victoza, the average steady state concentration of liraglutide over 24 hours was approximately 128 ng/mL. AUC0-∞ was equivalent between upper arm and abdomen, and between upper arm and thigh. AUC0-∞ from thigh was 22% lower than that from abdomen. Absolute bioavailability of liraglutide following subcutaneous administration is approximately 55%.
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
204656-20-2
n3:clearance
The mean apparent clearance following subcutaneous administration of a single dose of liraglutide is approximately 1.2 L/h